Navigation Links
Convergence Pharmaceuticals Announces Start of Phase II Study for its Selective Nav 1.7 blocker CNV1014802
Date:7/18/2011

CAMBRIDGE, England, July 19, 2011 /PRNewswire/ --


Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines, today announces that the Phase II proof of concept study with CNV1014802 for treating pain associated with lumbosacral radiculopathy (LSR) has started.

LSR is a common neuropathic pain condition caused by compression of the nerve roots in the lumbar region of the spine. Common features include pain radiating from the lower back down the legs, together with sensory and motor impairment in the lower limbs. LSR is a very high unmet medical need, affecting 3-5% of the global population and there are no drug treatments currently approved for treating this type of neuropathic pain.[1]

The Phase II trial is a randomised, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of orally administered CNV1014802 in patients with pain associated with LSR. It is an innovative study, incorporating a number of design features which will enhance confidence in the outcome of the study. The trial will run in four European countries and results are expected in the second half of 2012.

Clive Dix, Chief Executive Officer of Convergence Pharmaceuticals, added: "We are delighted to announce the start of this trial; the second clinical stage trial initiated since our conception as a Company in October 2011 and a testament to our innovative team. It is clear that safe, effective pain treatment is urgently required and we are focussed on driving forward the development of our pipeline to meet this need."

Commenting on the announcement, Simon Tate, Chief Scientific Officer of Convergence Pharmaceuticals, said: "We are very excited to be initiating this Phase II study for CNV1014802.  CNV1014802's differentiated and superior profile could have a significant impact on the treatment of patients with
'/>"/>

SOURCE Convergence Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Nano-Bio-Info-Cogno Revolutions to be Explored at Convergence08 Unconference - Forecaster Paul Saffo to Keynote
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
4. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
5. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
6. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
7. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
8. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
9. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
10. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
11. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2014)... October 18, 2014 The Asia-Pacific Liquid ... segments the concerned market in Asia-Pacific with analysis and ... million in 2013, and is expected to reach $380.0 ... 2013 to 2018. , Browse through the TOC of ... idea of the in-depth analysis provided. This also provides ...
(Date:10/18/2014)... October 18, 2014 According to a ... & Well Type - Global Trends & Forecasts up ... $31 billion in 2011. This value is expected to ... by 2017, with 10% CAGR during the same period. ... fracturing production market in terms of hydraulic horse power ...
(Date:10/17/2014)... have received a $451,781 Air Force Office of Scientific ... micro- and nano-scale level that will provide clues for ... Mechanical and Aerospace Engineering, said the new technology and ... X-rays of an aircraft,s wing., "We,ll be able to ... look at it on this scale," Huang said. "Certain ...
(Date:10/17/2014)... DE (PRWEB) October 17, 2014 ... among top employers, as published in today’s print ... Science Careers’ annual Top Employers Survey polled employees ... determine the 20 best employers. Rankings were ... were asked to rate their companies on 23 ...
Breaking Biology Technology:The Asia-Pacific Liquid Crystal on Silicon (LCoS) display market is expected to reach $380.0 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Liquid Crystal on Silicon (LCoS) display market is expected to reach $380.0 million by 2018 - New Report by MicroMarket Monitor 3Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 2Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 3Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 4UT Arlington project to detect possible damages in aircraft parts early in process 2DuPont Named Top Employer by Science Magazine 2DuPont Named Top Employer by Science Magazine 3
... - Prevenar Vaccine to Help Protect ... in Young Children Worldwide, Wyeth today ... Ireland have,initiated national immunisation programmes (NIPs) for ... adding Prevenar(TM) (Pneumococcal,Saccharide Conjugated Vaccine, Adsorbed), also ...
... has partnered,with ResMed, a leading manufacturer of medical ... a new wireless,technology used to monitor patients with ... technology is intended to more easily,provide data that ... care for those,requiring PAP treatment., "We take ...
... -- China Bio Energy,Holdings (OTC Bulletin Board: ... in the Susquehanna Second Annual Beijing Management ... Management,s participation will consist,of a presentation scheduled ... a.m.,local time as well one-on-one meetings with ...
Cached Biology Technology:Cyprus and Ireland Add Wyeth's 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation Schedules 2Cyprus and Ireland Add Wyeth's 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation Schedules 3Latest Sleep Disorder Technology Tested With SleepQuest 2China Bio Energy Holdings Group Announces Participation in the Susquehanna Second Annual Beijing Management Summit 2
(Date:10/15/2014)... awarded the 44th Rosenstiel Award for Distinguished Work in ... exploring the mechanisms of genomic instability and its implications ... the second alumnus to win the Rosenstiel Award; the ... , Alt is the Charles A. Janeway Professor of ... and an investigator at the Howard Hughes Medical Institute ...
(Date:10/14/2014)... Like discriminating thieves, prostate cancer tumors scavenge and hoard ... But such avarice may be a fatal weakness. ... to kill prostate cancer cells by delivering a trove ... the diseased cells brimming with the mineral, leaving non-cancer ... drugs already commercially available for other uses, could soon ...
(Date:10/14/2014)... Ohio (Oct. 14, 2014)—It,s been millions of years since ... a team led by Ohio University scientists is breathing ... model airflow through dinosaur snouts. The research has important ... only breathe but to enhance the sense of smell ... ,nosy, animals," said Ohio University doctoral student Jason Bourke, ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Prostate cancer's penchant for copper may be a fatal flaw 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3
... today announced that two Fred Hutchinson Cancer Research ... honor for scientists at the beginning of their ... Ph.D., and cancer-prevention researcher Ulrike "Riki" Peters, Ph.D., ... 2008 Presidential Early Career Award for Scientists and ...
... Springer will publish The HUGO Journal in cooperation ... Springer as Genomic Medicine, The HUGO Journal has ... Members of HUGO will receive free access to the ... discounted rates. The HUGO Journal will focus ...
... 40 member organizations of the International Tiger Coalition (ITC) applaud ... farming is too great a gamble for the world to ... wild. "Having carefully weighed the economics argument, we ... tiger products and for all countries to continue to ban ...
Cached Biology News:2 Fred Hutchinson Cancer Research Center scientists receive Presidential Early Career Award 22 Fred Hutchinson Cancer Research Center scientists receive Presidential Early Career Award 32 Fred Hutchinson Cancer Research Center scientists receive Presidential Early Career Award 4